Lois E Shepherd
Overview
Explore the profile of Lois E Shepherd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
4356
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kwon J, McTaggart-Cowan H, Ferguson S, Samouelian V, Lambaudie E, Guyon F, et al.
J Gynecol Oncol
. 2024 Oct;
35(6):e117.
PMID: 39453395
Objective: SHAPE (Simple Hysterectomy And PElvic node assessment) was an international phase III trial demonstrating that simple hysterectomy was non-inferior to radical hysterectomy for pelvic recurrence risk, but superior for...
2.
Kuruvilla J, Rushton C, Villa D, Aslam M, Prica A, Abdel Samad N, et al.
Br J Haematol
. 2024 Sep;
205(5):2067-2071.
PMID: 39267295
In the LY.17 randomized phase II clinical trial, adults with relapsed and refractory diffuse large B-cell lymphoma treated with ibrutinib-R-GDP (IR-GDP) for up to three cycles had more documented bacterial...
3.
Chapman J, Bayani J, SenGupta S, Bartlett J, Piper T, Quintayo M, et al.
J Clin Oncol
. 2024 Jun;
42(24):2887-2898.
PMID: 38824432
Purpose: ASCO/College of American Pathologists guidelines recommend reporting estrogen receptor (ER) and progesterone receptor (PgR) as positive with (1%-100%) staining. Statistically standardized quantitated positivity could indicate differential associations of positivity...
4.
Stewart D, Kuruvilla J, Lee D, Dudebout J, Chua N, Larouche J, et al.
Br J Haematol
. 2024 May;
205(3):881-890.
PMID: 38802107
The Canadian Cancer Trials Group (CCTG) LY.17 is an ongoing multi-arm randomized phase II trial evaluating novel salvage therapies compared with R-GDP (rituximab, gemcitabine, dexamethasone and cisplatin) in autologous stem...
5.
Plante M, Kwon J, Ferguson S, Samouelian V, Ferron G, Maulard A, et al.
N Engl J Med
. 2024 Feb;
390(9):819-829.
PMID: 38416430
Background: Retrospective data suggest that the incidence of parametrial infiltration is low in patients with early-stage low-risk cervical cancer, which raises questions regarding the need for radical hysterectomy in these...
6.
Goodwin P, Chen B, Gelmon K, Whelan T, Ennis M, Lemieux J, et al.
J Clin Oncol
. 2023 Sep;
41(35):5356-5362.
PMID: 37695982
JCO Metformin has been associated with lower cancer risk in epidemiologic and preclinical research. In the MA.32 randomized adjuvant breast cancer trial, metformin ( placebo) did not affect invasive disease-free...
7.
Harris L, Blanke C, Erba H, Ford J, Gray R, LeBlanc M, et al.
Clin Cancer Res
. 2023 Aug;
29(23):4728-4732.
PMID: 37531248
Basket, umbrella, and platform trial designs (master protocols) have emerged over the last decade to study precision medicine approaches in oncology. First-generation trials like NCI-MATCH (Molecular Analysis for Therapy Choice)...
8.
Gupta A, Hay A, Crump M, Djurfeldt M, Zhu L, Cheung M, et al.
Oncologist
. 2023 May;
28(9):799-803.
PMID: 37226534
Background: When cancer treatments have similar oncologic outcomes, the number of days with in-person healthcare contact (""contact days'') can help contextualize expected time use with each treatment. We assessed contact...
9.
Goodwin P, Chen B, Gelmon K, Whelan T, Ennis M, Lemieux J, et al.
JAMA
. 2022 May;
327(20):1963-1973.
PMID: 35608580
Importance: Metformin, a biguanide commonly used to treat type 2 diabetes, has been associated with potential beneficial effects across breast cancer subtypes in observational and preclinical studies. Objective: To determine...
10.
Asleh K, Tu D, Gao D, Bramwell V, Levine M, Pritchard K, et al.
Clin Cancer Res
. 2021 Oct;
27(23):6570-6579.
PMID: 34615722
Purpose: Accurate IHC biomarkers incorporating nestin positivity or inositol polyphosphate-4-phosphate (INPP4B) loss have recently been optimized to identify the basal-like intrinsic breast cancer subtype regardless of estrogen, progesterone, or Her2...